These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 20332487

  • 1. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, Finek J, Chottova-Dvorakova M, Babjuk M, Novak K, Stolz J.
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [Abstract] [Full Text] [Related]

  • 2. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
    Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Alvarez-Grave P, Lara-Padilla E.
    Clin Invest Med; 2009 Dec 01; 32(6):E258. PubMed ID: 20003831
    [Abstract] [Full Text] [Related]

  • 3. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
    Chen FP, Chen LL, Shen M, Chen W, Tao ZH, Wu XL, Hu YP, Li CD, Chen ZG, Chen XD.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 22; 88(4):261-4. PubMed ID: 18361839
    [Abstract] [Full Text] [Related]

  • 4. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
    Tao ZH, Mao XL, Wang CH, Chen XD, Yu KY, Weng ZL, Hu YP, Zhang XH, Xie H, Wang OC, Song QT, Li CD, Chen ZG.
    Zhonghua Nan Ke Xue; 2007 Feb 22; 13(2):130-3. PubMed ID: 17345768
    [Abstract] [Full Text] [Related]

  • 5. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
    Weng ZL, Yu KY, Mao XL, Tao ZH, Chen XD, Wu XL, Hu YP, Wang SQ, Li CD, Chen ZG.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 07; 86(41):2911-5. PubMed ID: 17288789
    [Abstract] [Full Text] [Related]

  • 6. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
    de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA.
    Cancer Res; 2002 May 01; 62(9):2695-8. PubMed ID: 11980670
    [Abstract] [Full Text] [Related]

  • 7. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
    Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG, Goulart LR.
    Clin Biochem; 2008 Oct 01; 41(14-15):1191-8. PubMed ID: 18640109
    [Abstract] [Full Text] [Related]

  • 8. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, Talesa VN.
    Biomarkers; 2009 Jun 01; 14(4):235-43. PubMed ID: 19489685
    [Abstract] [Full Text] [Related]

  • 9. [Detection of DD3 mRNA in the urine of prostate cancer patients and its clinical significance].
    Liu GX, Guo HQ, Li XG, Gan WD, Zeng LQ, Shi HL, Zhang SW, Liu TS.
    Zhonghua Nan Ke Xue; 2007 Jun 01; 13(6):511-3. PubMed ID: 17615974
    [Abstract] [Full Text] [Related]

  • 10. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue.
    Bialkowska-Hobrzanska H, Driman DK, Fletcher R, Harry V, Razvi H.
    Can J Urol; 2006 Feb 01; 13(1):2967-74. PubMed ID: 16515751
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER.
    Exp Mol Pathol; 2012 Feb 01; 92(1):13-9. PubMed ID: 21963599
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
    Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y.
    Clin Cancer Res; 2002 Jun 01; 8(6):1794-9. PubMed ID: 12060619
    [Abstract] [Full Text] [Related]

  • 16. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.
    Eur Urol; 2011 Nov 01; 60(5):1045-54. PubMed ID: 21871709
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular PCA3 diagnostics on prostatic fluid.
    van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.
    Prostate; 2007 Jun 01; 67(8):881-7. PubMed ID: 17440939
    [Abstract] [Full Text] [Related]

  • 19. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z, Liu J, Li S, Shen W.
    Prostate; 2009 Sep 01; 69(12):1292-302. PubMed ID: 19462463
    [Abstract] [Full Text] [Related]

  • 20. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.